readthroughSign in
Sep 9, 2026Clinical readout

Anavex says FDA agreed to meeting on adding children to Rett syndrome Phase 3 trial

Anavex Life Sciences disclosed on September 9, 2026 that the FDA granted its request for a meeting on including pediatric patients in the Phase 3 trial of blarcamesine for Rett syndrome.

Anavex Life Sciences Corp. disclosed in an 8-K filing dated September 9, 2026 that the FDA had agreed to meet with the company to discuss expanding its planned Phase 3 trial of ANAVEX 2-73 (blarcamesine) in Rett syndrome to include pediatric patients, in addition to the adult population already planned for the study. On September 9, 2026, the Company disclosed that the U.S. Food and Drug Administration has granted the Company's request for a meeting to discuss inclusion of pediatric patients in its Phase 3 clinical trial for ANAVEX 2-73 in Rett syndrome.1

The filing noted that Anavex has been advancing its blarcamesine development program across three indications in the United States: early Alzheimer's disease, Rett syndrome, and Fragile X syndrome. The company said it is moving forward with initiation of a Phase 3 trial for ANAVEX 2-73 in adult Rett syndrome patients, identified as study ANAVEX 2-73-RS-005.1

The 8-K was filed under Item 8.01, Other Events, and signed by Sandra Boenisch, the company's Principal Financial Officer and Treasurer. The filing was submitted on behalf of Anavex Life Sciences Corp. and dated September 9, 2026.1 The company is based in New York and trades on the Nasdaq Stock Market under the ticker AVXL. No additional details on the timing of the FDA meeting or further trial design changes were included in the filing.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.